The official source for Kihealth press releases, scientific milestones, partnerships, awards, and company announcements.
From scientific validation to recognition, financing, and partnerships — milestones marking Kihealth's path from breakthrough discovery to a commercial-stage platform company.
Kihealth launched a $15 million Series A financing to accelerate commercialization of the Intercept IQ™ platform, expand pharmaceutical partnerships, and advance disease interception diagnostics across metabolic disease, oncology, and neuroscience.
Kihealth launched its Intercept IQ™ platform alongside the BetaIntercept™ portfolio for Type 1 and Type 2 diabetes, while expanding development into oncology (OncoIntercept™) and neuroscience (NeuroIntercept™) through a single tissue-specific molecular diagnostics platform.
Kihealth announced the launch of Beta Intercept™, its next-generation beta-cell cell-free DNA assay built on the Intercept IQ™ molecular intelligence platform. The assay measures active beta-cell injury in real time, offering the potential for earlier detection, improved disease monitoring, and precision therapeutic development across Type 1 and Type 2 diabetes.
Kihealth was named the 2025 KidsX Pediatric Innovation People's Choice Award winner after presenting its breakthrough beta-cell detection platform. The recognition highlights the growing need for earlier diagnosis of pediatric metabolic and autoimmune disease.
Kihealth announced the successful close of its oversubscribed $5 million seed financing, supporting commercialization of its first molecular diagnostic for beta-cell apoptosis and expansion of the Intercept IQ platform.
Kihealth received the American Diabetes Association Innovation of the Year Award during the 85th Scientific Sessions, recognizing its liquid biopsy technology for measuring pancreatic beta-cell death and enabling earlier diabetes detection.
GrowFL selected Kihealth as a finalist for the 15th Annual Florida Companies to Watch Awards, recognizing the company's innovation, rapid growth, and contribution to Florida's life sciences ecosystem.
Kihealth validated its proprietary BetaIntercept™ assay, a Yale University-developed molecular diagnostic that directly measures pancreatic beta-cell apoptosis through tissue-specific cfDNA, detecting diabetes years before conventional biomarkers.
Kihealth and Genova Diagnostics announced a strategic partnership to make advanced gut health testing available directly to consumers through retail pharmacies and online distribution, expanding access to preventive diagnostic testing.
Our communications team is available for press inquiries, interviews, and background briefings. Reach out and we'll connect you with the right contact.